Filtered By:
Specialty: Drugs & Pharmacology
Condition: Dementia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 176 results found since Jan 2013.

Ginkgo biloba extract EGb 761 ® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial
Conclusion: Over the 24-week period, EGb 761® treatment improved overall cognitive performance among patients with mild to moderate ischemic stroke. Our findings provide valuable recommendations for the design of future trials, including the criteria for patient selection.Clinical Trial Registration:www.isrctn.com, identifier ISRCTN11815543.
Source: Frontiers in Pharmacology - March 29, 2023 Category: Drugs & Pharmacology Source Type: research

Stimulation of angiotensin II receptor 2 preserves cognitive function and is associated with an enhanced cerebral vascular density after stroke
In conclusion, C21 prevented cognitive impairment after stroke, likely through a mechanism involving vascular protection and restoration.PMID:34481068 | DOI:10.1016/j.vph.2021.106904
Source: Vascular Pharmacology - September 4, 2021 Category: Drugs & Pharmacology Authors: Wael Eldahshan Mohammed A Sayed Mohamed E Awad Heba A Ahmed Ellen Gillis Waleed Althomali Bindu Pillai Abdulkarim Alshammari Ladonya Jackson Guangkuo Dong Jennifer C Sullivan Marion A Cooley Mohammed Elsalanty Adviye Ergul Susan C Fagan Source Type: research

Delayed revascularization in acute ischemic stroke patients
Stroke shares a significant burden of global mortality and disability. A significant decline in the quality of life is attributed to the so-called post-stroke cognitive impairment including mild to severe cognitive alterations, dementia, and functional disability. Currently, only two clinical interventions including pharmacological and mechanical thrombolysis are advised for successful revascularization of the occluded vessel. However, their therapeutic effect is limited to the acute phase of stroke onset only. This often results in the exclusion of a significant number of patients who are unable to reach within the therap...
Source: Frontiers in Pharmacology - February 8, 2023 Category: Drugs & Pharmacology Source Type: research

Cardiac Biomarkers in Stroke, Alzheimer's Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations.
Abstract Conventionally cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as "cardiac diseases," especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer's disease. Alzheimer's disease is also one of the other CNS conditions where measuring cardiac biom...
Source: CNS and Neurological Disorders Drug Targets - October 5, 2020 Category: Drugs & Pharmacology Authors: Khan S, Kamal MA Tags: CNS Neurol Disord Drug Targets Source Type: research

Selecting the right anticoagulant for stroke prevention in atrial fibrillation
CONCLUSIONS: Non-valvular AF patients on apixaban had lower rates of thromboembolic events than the patients on acenocumarol. This article will serve as a reminder of the positive health and financial outcomes of apixaban use, especially to those healthcare systems that are still oblivious to the decrease in economic burden and gain in quality-adjusted life years (QALY) by the long-term use of NOACS/ DOACS instead of the AVK anticoagulants.PMID:34286492 | DOI:10.26355/eurrev_202107_26241
Source: Pharmacological Reviews - July 21, 2021 Category: Drugs & Pharmacology Authors: N R Kundnani C I Rosca A Sharma A Tudor M S Rosca D D Nisulescu H S Branea V Mocanu D C Crisan D R Buzas S Morariu D F Lighezan Source Type: research

Patient ‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke
ConclusionsOur findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - November 30, 2016 Category: Drugs & Pharmacology Authors: Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Vasil Hricak, Jan Murin, Peter Kukumberg, Tomas Tesar, Adam Hloska, Rashmi Shah Tags: Original Report Source Type: research